ImpriMed, Inc.
Veterinary Medicine · Artificial Intelligence

ImpriMed, Inc. news and milestones

ImpriMed, Inc.: 18 headlines on record, 5 headlines in the last 90 days. Its story counts 4 milestones.

Data updated Nov 17, 2026 · Back to the company report
18Headlines
5In 90 days
4Milestones

Headlines

Sep 292026
News · Pharmacy Times
AI-powered drug response prediction technology is revolutionizing veterinary and human oncology by enabling personalized treatment plans through live cell testing, machine learni…
Sep 292026
News · Pharmacy Times
Dogs share a number of cancers with humans, including melanoma, non-Hodgkin lymphoma, leukemia, and osteosarcoma.
Sep 292026
News · dvm360
ImpriMed has announced the launch of the Drug Response Predictions service used to forecast how each dog will respond to certain oncology treatments.
Sep 292026
News · dvm360
A new study showed that this cell-sizing method is useful for characterizing feline lymphoma and predicting patient survival time
Jul 12026
Press release · businesswire
ImpriMed CEO Dr. Sungwon Lim to speak at the NCI's functional precision medicine workshop, underscoring the company's leadership in the growing field.
Jun 12, 20242024
News · Pulse 2.0
ImpriMed is a company that provides personalized medicine easily accessible for pets with blood cancer diseases. Pulse 2.0 interviewed ImpriMed CEO and co-founder Sungwon Lim to…
Jan 29, 20242024
News · The Daily Beast
A tech startup wants to use AI to help veterinarians give targeted drugs for a dog's cancer treatment-but is it a helpful tool or are they barking up the wrong tree?
Dec 21, 20232023
News · Pulse 2.0
ImpriMed - a leading precision medicine startup focused on utilizing AI to improve cancer treatment, recently announced the close of a $23 million Series A funding round, led by…
Dec 19, 20232023
News · TechCrunch
ImpriMed, a California-based precision medicine startup, builds AI-powered dog cancer treatment technology that helps veterinarians identify the most
May 24, 20212021
News · YahooFinance
PALO ALTO, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- ImpriMed, Inc., a leading veterinary precision medicine biotech startup today announced the launching of their most advanced p…
News · synbiobeta.com
Blood cancer samples are easy to draw and nearly impossible to study. One company fixed that in its first year, then spent eight more earning the right to sell it.
News · veterinary-practice.com
News · link.springer.com
Sources: the outlets named on each headline, each story once

Milestones

Each milestone is dated by its source: registers, filings, the press

How to cite

ImpriMed, Inc., News. Alion, Nov 17, 2026. https://alion.io/company/imprimedicine/news

.json · .md · CC BY-SA 4.0